Qritive, a leading developer of artificial intelligence (AI)-powered cancer diagnostics, and, Corista, a leading provider of clinical, research and educational digital pathology image management solutions, are announcing a new partnership in digital pathology. Through the partnership, Qritive's artificial intelligence modules and Corista's DP3® image management platform will be integrated to help pathologist's focus their time towards more complex case work. The combined solution enables computational modules to screen for prostate and colon cancers, quantify IHC markers, and detect lymph node metastasis.

With this integrated solution, pathologists will be able to increase their efficiency by prioritizing and grading specific cases, while improving the detection of difficult to diagnose cancers. This enhanced digital pathology workflow will allow for pre-reviewed AI analysis of digital pathology images utilizing any whole slide image scanning device and laboratory information system (LIS).

Corista's industry-leading clinical image management system DP3 is DICOM-compliant, enables voice collaborations, remote case review, global consults, integrated image analysis with both in-house and commercially available systems, and a proprietary LIS Connector— all in one platform. Combined with Qritive's AI modules for prostate, colon, lymph metastasis, and the quantification of IHC markers, the integrated solution will support pathologists in making the highest quality diagnoses, while freeing their time for the review of challenging cases.

"Qritive is pushing new frontiers in pathology with Al that is safe, adaptable, and reliable for clinical use," said&nbsp;Aneesh Sathe, CEO and Co-founder of Qritive. Mr. Sathe continued to state "Corista's&nbsp;image management system combined with the assistive power of Qritive's&nbsp;AI modules is the ideal workbench for pathologists to conduct diagnostics with ease, consistency, and precision."

Corista's DP3 platform was built in conjunction with some of the most respected pathology centers at leading medical centers in the US, specifically for clinical-grade pathology use cases. Today, DP3 is the digital pathology platform of choice for many of the largest medical centers across the country", said&nbsp;Liz Wingard, CEO and Co-founder of Corista. "Our partnership with Qritive will advance the use of artificial intelligence applications to support the growing demands on pathologists to keep up with the pace of their workloads, and the challenges of cancer diagnosis."

With operations in USA,&nbsp;Singapore, and&nbsp;India, Qritive is a breakthrough Artificial Intelligence (AI) solution developer that is advancing digital pathology for cancer diagnosis, enhancing imaging accuracy and improving health outcomes. Qritive expands on deep-learning technology to provide automated interpretation of pathology tests for time and resource-strapped medical imaging professionals - enabling faster diagnosis and reducing time to treatment for patients. Its AI-powered solutions empower healthcare professionals across the globe to operate collaboratively at the peak of their performance despite complexity and distance. For more information, visit us&nbsp;<a href="https://bit.ly/qritive-corista-20230227" target="_blank" rel="nofollow">here</a>.

Corista's DP3® digital pathology image management system is unlocking the scale, reach and utility of digital pathology for physicians, scientists, and researchers around the world. The industry leading, only pathology-focused software with DICOM compliance and ability to natively read every scanner's image format, DP3 integrates universal image access with a full suite of workflow, voice collaboration, search and integrated image analysis functionality. DP3's scalable and secure platform is accessible from any web-enabled device, putting the power of universal access and analysis together with proven LIS integration. DP3 is the industry's most comprehensive digital pathology platform and the winner of Frost &amp; Sullivan's Product Innovation Award. For more information visit&nbsp;<a href="http://www.corista.com/" target="_blank" rel="nofollow">www.corista.com</a>

<h1>Qritive and Corista Announce Partnership to Advance the Use of Computational Digital Pathology Workflows with Integrated Image Management</h1>Qritive, a leading developer of artificial intelligence (AI)-powered cancer diagnostics, and, Corista, a leading provider of clinical, research and educational digital pathology image management solutions, are announcing a new partnership in digital pathology. Through the partnership, Qritive's artificial intelligence modules and Corista's DP3® image management platform will be integrated to help pathologist's focus their time towards more complex case work. The combined solution enables computational modules to screen for prostate and colon cancers, quantify IHC markers, and detect lymph node metastasis.With this integrated solution, pathologists will be able to increase their efficiency by prioritizing and grading specific cases, while improving the detection of difficult to diagnose cancers. This enhanced digital pathology workflow will allow for pre-reviewed AI analysis of digital pathology images utilizing any whole slide image scanning device and laboratory information system (LIS).Corista's industry-leading clinical image management system DP3 is DICOM-compliant, enables voice collaborations, remote case review, global consults, integrated image analysis with both in-house and commercially available systems, and a proprietary LIS Connector— all in one platform. Combined with Qritive's AI modules for prostate, colon, lymph metastasis, and the quantification of IHC markers, the integrated solution will support pathologists in making the highest quality diagnoses, while freeing their time for the review of challenging cases."Qritive is pushing new frontiers in pathology with Al that is safe, adaptable, and reliable for clinical use," said&nbsp;Aneesh Sathe, CEO and Co-founder of Qritive. Mr. Sathe continued to state "Corista's&nbsp;image management system combined with the assistive power of Qritive's&nbsp;AI modules is the ideal workbench for pathologists to conduct diagnostics with ease, consistency, and precision."Corista's DP3 platform was built in conjunction with some of the most respected pathology centers at leading medical centers in the US, specifically for clinical-grade pathology use cases. Today, DP3 is the digital pathology platform of choice for many of the largest medical centers across the country", said&nbsp;Liz Wingard, CEO and Co-founder of Corista. "Our partnership with Qritive will advance the use of artificial intelligence applications to support the growing demands on pathologists to keep up with the pace of their workloads, and the challenges of cancer diagnosis."About QritiveWith operations in USA,&nbsp;Singapore, and&nbsp;India, Qritive is a breakthrough Artificial Intelligence (AI) solution developer that is advancing digital pathology for cancer diagnosis, enhancing imaging accuracy and improving health outcomes. Qritive expands on deep-learning technology to provide automated interpretation of pathology tests for time and resource-strapped medical imaging professionals - enabling faster diagnosis and reducing time to treatment for patients. Its AI-powered solutions empower healthcare professionals across the globe to operate collaboratively at the peak of their performance despite complexity and distance. For more information, visit us&nbsp;<a href="https://bit.ly/qritive-corista-20230227" target="_blank" rel="nofollow">here</a>.About CoristaCorista's DP3® digital pathology image management system is unlocking the scale, reach and utility of digital pathology for physicians, scientists, and researchers around the world. The industry leading, only pathology-focused software with DICOM compliance and ability to natively read every scanner's image format, DP3 integrates universal image access with a full suite of workflow, voice collaboration, search and integrated image analysis functionality. DP3's scalable and secure platform is accessible from any web-enabled device, putting the power of universal access and analysis together with proven LIS integration. DP3 is the industry's most comprehensive digital pathology platform and the winner of Frost &amp; Sullivan's Product Innovation Award. For more information visit&nbsp;<a href="http://www.corista.com/" target="_blank" rel="nofollow">www.corista.com</a>

Fitness / Healthcare

Medical / Hospital

Pharmaceuticals

Health and Beauty appliances

Qritive and Corista Announce Partnership to Advance the Use of Computational Digital Pathology Workflows with Integrated Image Management

QAi Prostate leverages advanced machine learning algorithms to accurately identify and classify malignant and benign areas in prostate biopsies, improving diagnostic accuracy and patient outcomes &nbsp;&nbsp;

<a href="https://qritive.com/" target="_blank" rel="nofollow">Qritive</a>,&nbsp;a leading provider of digital pathology solutions, announced the launch of a new AI (Artificial Intelligence) module, QAi Prostate, for prostate cancer diagnosis. Using advanced machine learning algorithms, QAi Prostate analyzes whole slide images of prostate core needle biopsies, identifies prostatic adenocarcinoma region, and segments and classifies them into benign and malignant areas. &nbsp;&nbsp;

Prostate adenocarcinoma is the most common form of prostate cancer, accounting for approximately 90% of all prostate cases. QAi Prostate is a powerful tool that utilizes both whole slide images and regions of interest (ROI) for screening adenocarcinoma. After identifying and classifying the benign and malignant tumor areas in biopsy tissue samples, it provides a detailed summary explaining the tumor size and percentage for each slide or ROI. This helps pathologists make a more informed and accurate diagnosis quickly, thereby reducing time to treatment for patients. &nbsp;

Capabilities central to the QAi Prostate module include:

Intelligent AI-based tumor classification:&nbsp;Distinct segmentation boundaries to segregate the benign and malignant areas provide clear visual representation for quicker assessment by the pathologists.Enriched and Detailed AI summary:&nbsp;Analyzed key parameters are represented in user-friendly graphical and tabular forms for ease of use by pathologists and clinicians.Automated screening:&nbsp;Once a lab's cases are uploaded, the QAi Prostate module analyzes the cases and can automatically initiate screening, triage, and prioritization of cases for pathologists' final review, increasing their productivity.

QAi Prostate was developed using a rich dataset and has undergone testing and validation to ensure its clinical metrics and reliability. It can work with any standard digital pathology system and can be easily integrated into existing workflows using Open API interface through a customizable middleware. It includes secured communication using standard SSL encryption and the middleware as a single point of entry with role-based access to ensure advanced security and compliance. QAi Prostate can be deployed for research use or as laboratory developed test only. It is currently not approved by the FDA or CE marked.

"We are excited to introduce this new AI module for prostate cancer diagnosis," said Dr.&nbsp;Kaveh Taghipour, CTO of Qritive. "QAi Prostate has been developed using millions of data points and thousands of hours of expert knowledge. This technology has the potential to improve the accuracy and speed of prostate cancer diagnosis significantly, leading to better outcomes for patients."

The launch of QAi Prostate is part of Qritive's ongoing commitment to innovation to provide the best clinical AI solutions for cancer diagnosis and advance health equity. The company is dedicated to empowering healthcare professionals across the globe with AI-powered solutions to operate collaboratively at the peak of their performance despite complexity and distance.

For more information about&nbsp;QAi&nbsp;Prostate, please visit Qritive's&nbsp;<a href="https://qritive.com/pr230310" target="_blank" rel="nofollow">website</a>.

Headquartered&nbsp;in&nbsp;Singapore, with operations in US &amp;&nbsp;India, Qritive is a breakthrough Artificial Intelligence (AI) solution developer that is advancing digital pathology for cancer diagnosis and improving health outcomes with the assistance of AI based solutions. Qritive expands on deep learning technology to provide automated interpretation of pathology tests for time and resource-strapped medical imaging professionals - enabling faster diagnosis and reducing time to treatment for patients. Qritive is dedicated to empowering healthcare professionals across the globe with AI-powered solutions to operate collaboratively at the peak of their performance despite complexity and distance.

<h1>Qritive Launches QAi Prostate: Advanced AI-Powered Prostate Cancer Diagnosis Tool for Pathologists</h1>QAi Prostate leverages advanced machine learning algorithms to accurately identify and classify malignant and benign areas in prostate biopsies, improving diagnostic accuracy and patient outcomes &nbsp;&nbsp;<a href="https://qritive.com/" target="_blank" rel="nofollow">Qritive</a>,&nbsp;a leading provider of digital pathology solutions, announced the launch of a new AI (Artificial Intelligence) module, QAi Prostate, for prostate cancer diagnosis. Using advanced machine learning algorithms, QAi Prostate analyzes whole slide images of prostate core needle biopsies, identifies prostatic adenocarcinoma region, and segments and classifies them into benign and malignant areas. &nbsp;&nbsp;Prostate adenocarcinoma is the most common form of prostate cancer, accounting for approximately 90% of all prostate cases. QAi Prostate is a powerful tool that utilizes both whole slide images and regions of interest (ROI) for screening adenocarcinoma. After identifying and classifying the benign and malignant tumor areas in biopsy tissue samples, it provides a detailed summary explaining the tumor size and percentage for each slide or ROI. This helps pathologists make a more informed and accurate diagnosis quickly, thereby reducing time to treatment for patients. &nbsp;Capabilities central to the QAi Prostate module include:Intelligent AI-based tumor classification:&nbsp;Distinct segmentation boundaries to segregate the benign and malignant areas provide clear visual representation for quicker assessment by the pathologists.Enriched and Detailed AI summary:&nbsp;Analyzed key parameters are represented in user-friendly graphical and tabular forms for ease of use by pathologists and clinicians.Automated screening:&nbsp;Once a lab's cases are uploaded, the QAi Prostate module analyzes the cases and can automatically initiate screening, triage, and prioritization of cases for pathologists' final review, increasing their productivity.QAi Prostate was developed using a rich dataset and has undergone testing and validation to ensure its clinical metrics and reliability. It can work with any standard digital pathology system and can be easily integrated into existing workflows using Open API interface through a customizable middleware. It includes secured communication using standard SSL encryption and the middleware as a single point of entry with role-based access to ensure advanced security and compliance. QAi Prostate can be deployed for research use or as laboratory developed test only. It is currently not approved by the FDA or CE marked."We are excited to introduce this new AI module for prostate cancer diagnosis," said Dr.&nbsp;Kaveh Taghipour, CTO of Qritive. "QAi Prostate has been developed using millions of data points and thousands of hours of expert knowledge. This technology has the potential to improve the accuracy and speed of prostate cancer diagnosis significantly, leading to better outcomes for patients."The launch of QAi Prostate is part of Qritive's ongoing commitment to innovation to provide the best clinical AI solutions for cancer diagnosis and advance health equity. The company is dedicated to empowering healthcare professionals across the globe with AI-powered solutions to operate collaboratively at the peak of their performance despite complexity and distance.For more information about&nbsp;QAi&nbsp;Prostate, please visit Qritive's&nbsp;<a href="https://qritive.com/pr230310" target="_blank" rel="nofollow">website</a>.About QritiveHeadquartered&nbsp;in&nbsp;Singapore, with operations in US &amp;&nbsp;India, Qritive is a breakthrough Artificial Intelligence (AI) solution developer that is advancing digital pathology for cancer diagnosis and improving health outcomes with the assistance of AI based solutions. Qritive expands on deep learning technology to provide automated interpretation of pathology tests for time and resource-strapped medical imaging professionals - enabling faster diagnosis and reducing time to treatment for patients. Qritive is dedicated to empowering healthcare professionals across the globe with AI-powered solutions to operate collaboratively at the peak of their performance despite complexity and distance.